Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Silver Diamine Fluoride for Caries in Primary Teeth in Routine Clinical Practice

NCT07926828 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2026-09-17
Last updated
2026-11-09

Condition(s) studied

Dental Caries

Investigational drug(s) / intervention(s)

Silver diamine fluoride 38% →

Silver diamine fluoride 38%: Topical application of 38% silver diamine fluoride to caries lesions in primary teeth, following section 4.3 ("Guidelines for the use of SDF in primary and community care") of the Catalan Health Department guideline, as part of routine clinical practice.

Study summary

The goal of this observational study is to learn how well and how safely silver diamine fluoride (SDF) stops tooth decay (caries) in baby teeth when it is used in routine dental care. It will include children aged 14 years or younger with caries in their primary (baby) teeth who are treated with SDF at a public primary care dental clinic. The main questions it aims to answer are:

* What proportion of caries lesions treated with SDF do not progress after 12 months?
* How often do side effects occur, such as black staining of the tooth, sensitivity, abscesses, gum or skin irritation, or allergy?
* How satisfied are parents with the treatment? Participants will receive SDF as part of their usual dental care and will attend check-up visits 1, 6, and 12 months after treatment, where the dentist will examine the treated teeth, assess oral hygiene, and ask about diet and any side effects. Parents will answer a short satisfaction questionnaire.

Eligibility

Sex
ALL
Min age
—
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: * Boys and girls aged 14 years or younger * Caries in primary teeth with an indication for SDF treatment according to section 4 of the Catalan Health Department guideline "Implementation of silver diamine fluoride treatment in primary and community care dental clinics: rationale and protocol for use" * Signed informed consent from the parent or legal representative * For participants aged 12 years or older, signed informed assent adapted to their level of understanding, in addition to the consent of their legal representatives Exclusion Criteria: * Spontaneous or provoked pain associated with the caries lesion * Deep caries lesion close to the dental pulp, according to the investigator's judgment * Objection by the parents or the child to the black staining caused by SDF * Irreversible pulpitis or pulp necrosis * Active oral ulcers or gingivostomatitis * History of allergy to silver, ammonia, or iodine * Participation in another study involving an experimental intervention during the period of this study and/or with a visit schedule incompatible with this study

Primary outcome measure(s)

  • Proportion of treated caries lesions without progression — 12 months after SDF application
    Number of caries lesions without progression divided by the total number of caries lesions treated with SDF. Progression (yes/no) is rated by the investigator based on visual appearance, tactile assessment with a dental probe, absence of symptoms, stability over time, and radiographs if needed.

Trial sites (1)

FacilityCityRegionStatus
Baix a Mar Integrated Primary Care Center Vilanova i la Geltrú Barcelona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07926828 on ClinicalTrials.gov ↗ ← All trials in Spain